Meridian Management Co. Buys Shares of 9,221 ResMed Inc. $RMD

Meridian Management Co. purchased a new position in ResMed Inc. (NYSE:RMD) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 9,221 shares of the medical equipment provider’s stock, valued at approximately $2,524,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RMD. Pittenger & Anderson Inc. lifted its position in shares of ResMed by 4.4% during the third quarter. Pittenger & Anderson Inc. now owns 97,952 shares of the medical equipment provider’s stock valued at $26,812,000 after buying an additional 4,122 shares during the last quarter. Impact Partnership Wealth LLC bought a new position in shares of ResMed during the 3rd quarter worth approximately $734,000. Tandem Investment Advisors Inc. raised its stake in shares of ResMed by 1.5% during the 3rd quarter. Tandem Investment Advisors Inc. now owns 505,216 shares of the medical equipment provider’s stock worth $138,293,000 after acquiring an additional 7,315 shares in the last quarter. Archer Investment Corp lifted its position in ResMed by 3,990.9% during the third quarter. Archer Investment Corp now owns 900 shares of the medical equipment provider’s stock valued at $246,000 after acquiring an additional 878 shares during the last quarter. Finally, Fidelis Capital Partners LLC boosted its stake in ResMed by 8.1% in the third quarter. Fidelis Capital Partners LLC now owns 1,274 shares of the medical equipment provider’s stock valued at $349,000 after acquiring an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Insider Activity at ResMed

In other ResMed news, CEO Michael J. Farrell sold 8,011 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $249.75, for a total transaction of $2,000,747.25. Following the completion of the sale, the chief executive officer owned 467,866 shares of the company’s stock, valued at approximately $116,849,533.50. The trade was a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Witte Jan De sold 2,055 shares of ResMed stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $255.00, for a total value of $524,025.00. Following the completion of the transaction, the director directly owned 4,261 shares in the company, valued at $1,086,555. This represents a 32.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 21,594 shares of company stock worth $5,403,495. 0.65% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on RMD shares. UBS Group reaffirmed a “buy” rating and set a $345.00 price target on shares of ResMed in a research report on Friday, December 12th. Mizuho lowered their price target on ResMed from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Friday, October 31st. KeyCorp raised their target price on ResMed from $298.00 to $299.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Royal Bank Of Canada boosted their target price on shares of ResMed from $300.00 to $303.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Finally, Morgan Stanley set a $305.00 price target on shares of ResMed in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and a consensus price target of $296.09.

ResMed Trading Up 0.0%

Shares of RMD opened at $257.83 on Friday. ResMed Inc. has a fifty-two week low of $199.92 and a fifty-two week high of $293.81. The stock has a fifty day moving average of $250.90 and a two-hundred day moving average of $263.20. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.13 and a current ratio of 2.89. The company has a market capitalization of $37.63 billion, a PE ratio of 26.39, a price-to-earnings-growth ratio of 1.73 and a beta of 0.88.

ResMed (NYSE:RMD) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.13. The firm had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.40 billion. ResMed had a return on equity of 25.45% and a net margin of 27.35%.The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.43 earnings per share. As a group, analysts forecast that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Thursday, February 12th. ResMed’s dividend payout ratio is presently 24.56%.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat expectations — revenue rose ~11% to $1.423B and GAAP/non‑GAAP EPS came in above estimates (GAAP diluted EPS $2.68, non‑GAAP $2.81), reflecting solid demand for sleep and respiratory devices. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Positive Sentiment: Margins and profitability improved materially — gross margin expanded ~320 bps to 61.8% and non‑GAAP operating income/eps grew mid‑teens, boosting operating leverage. ResMed beats quarterly profit estimates on strong demand for its sleep devices
• Positive Sentiment: Shareholder returns and cash flow — board declared a $0.60 quarterly dividend (record Feb 12, payable Mar 19), company repurchased ~704k shares for $175M this quarter and generated $340M of operating cash flow. These support capital allocation and signal confidence. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Positive Sentiment: Product and digital‑health catalysts — FDA cleared an AI‑enabled device (“Smart Comfort”) to personalize CPAP comfort and improve adherence, reinforcing ResMed’s AI/digital ecosystem positioning. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Positive Sentiment: Immediate market reaction — coverage and headlines around the beat/margins lifted sentiment and shares traded up in early reaction. ResMed shares rise 2% as Q2 earnings top estimates, margins improve
• Neutral Sentiment: Investor events/webcast — management hosted the Q2 webcast and reiterated long‑term digital growth strategy at JPM; useful for model/ask sessions but not an immediate earnings surprise. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Negative Sentiment: Rising operating expenses and one‑time charges — SG&A and R&D rose (SG&A +12% YoY on a constant currency basis) and ResMed recorded ~$6M of restructuring charges, which could pressure near‑term margins if expenses stay elevated. Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
• Negative Sentiment: Insider selling noted in data summaries — multiple insider sales were reported recently (no open‑market purchases), which some investors view as a near‑term red flag. Resmed Inc. Reports 11% Revenue Growth and Strong Margin Improvement in Q2 Fiscal Year 2026

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.